What is DSIP?

DSIP stands for delta sleep-inducing peptide, a nine-amino-acid neuropeptide named from older sleep-physiology observations. [1][2][3]

The name is stronger than the practical evidence. DSIP is discussed for sleep, stress, pain, and withdrawal contexts, but the literature is older, mixed, and not a modern approved insomnia-drug program. [1][2][3]

DSIP is not a guaranteed sleep switch. It is better framed as a neuropeptide with sleep-related history and limited current clinical confidence. [1][2][3]

What DSIP is investigated for

DSIP evidence is grouped by practical use case and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

Sleep quality and sleep architecture

Injectable

43% Preliminary

Sleep has the main DSIP evidence base, but that evidence is old and not definitive. [1][2][4]

Human evidence

Older double-blind insomnia studies evaluated DSIP effects on chronic insomnia and sleep-wake behavior. [1][2][4]

Animal / mechanistic evidence

Review literature frames DSIP as a sleep-onset and sleep-architecture research tool with unresolved mechanism. [1][2][4]

Pain modulation

Injectable

38% Preliminary

Pain modulation is a small clinical signal that should be separate from sleep claims. [3][5]

Human evidence

A clinical pilot study evaluated DSIP in patients with chronic pronounced pain episodes. [3][5]

Animal / mechanistic evidence

Later review literature treats pain modulation as part of the unresolved DSIP pharmacology picture. [3][5]

Stress response modulation

Injectable

30% Limited

Stress-response claims remain mechanistic and unresolved. [6][7][8]

Human evidence

Human stress-response outcomes are not established in the cited DSIP literature. [6][7][8]

Animal / mechanistic evidence

Older DSIP reviews discuss stress and neuroendocrine hypotheses without settling the mechanism. [6][7][8]

Stroke neurorecovery

Injectable

28% Limited

Stroke neurorecovery is animal-only and separate from sleep evidence. [10]

Human evidence

Human stroke-recovery outcome evidence for DSIP is not established in the cited literature. [10]

Animal / mechanistic evidence

A rat focal-stroke model reported motor-function recovery after DSIP exposure. [10]

Evidence snapshot

Overall confidence

Preliminary

43%

DSIP has older sleep-focused human literature plus mechanistic interest, but practical usefulness remains uncertain. Modern insomnia-level evidence is weak. [1][2][3][4]

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

43%

Human evidence

Preliminary

Older human sleep literature exists but does not establish a modern insomnia treatment. [1][2][3][4]

33%

Animal / preclinical

Limited

Mechanistic and early clinical observations support sleep-related interest, with weaker support for stress and pain outcomes. [1][2][3][4]

43%

Mechanism support

Preliminary

DSIP has been studied around sleep architecture, stress-axis modulation, pain, and neuroendocrine signaling. The proposed effect is state modulation rather than a sedative-hypnotic drug profile. [1][2][3][4]

Forms & administration

DSIP is tracked as an injectable sleep-oriented peptide. Bedtime protocol patterns are separate from approved insomnia medicines and other sleep aids. [13][1][2]

Injectable

Dosing & protocols

The notes below separate published trial design from commonly discussed cosmetic or compounded-use patterns. They are educational context only, not a prescription or product instruction.

Typical Range

Common injectable protocols usually use 100-300 mcg per dose. [13][1][2]

Frequency

Common injectable schedules use nightly dosing during a short sleep-log block. [13][1][2]

Timing Considerations

The common timing anchor is 30-60 minutes before bed; daytime use can blur fatigue and sedation notes. [13][1][2]

Cycle Length

Common sleep-oriented blocks run 2-6 weeks before comparing sleep onset, awakenings, next-day fatigue, and adverse effects. [13][1][2]

What to expect

First few nights

Injectable DSIP sleep-oriented use may change sleep onset, nighttime awakenings, dream intensity, or morning restfulness. [1][2][3][4][13]

Weeks 2-4

Injectable sleep blocks may show as steadier sleep continuity, recovery feel, and next-day alertness. [1][2][3][4][13]

After stopping

Sleep patterns may drift back toward baseline after injectable DSIP exposure ends if the benefit depends on continued use. [1][2][3][4][13]

Safety profile

DSIP safety is a sleep-neuropeptide question: next-day sedation, dream changes, headache, sedative combinations, and limited modern human data are the main issues. [1][2][3][4]

Common side effects

Morning grogginess [1][2][3][4]
Vivid dreams [1][2][3][4]
Headache [1][2][3][4]

Cautions

Sedatives / alcohol [1][2][3][4]
Mood / sleep disorder [1][2][3][4]
Product quality [1][2][3][4]

What we don't know

Modern dose-ranging, interaction data, long-term sleep effects, and special-population safety remain limited. [1][2][3][4]

Who DSIP is not for

Route-specific avoid and medical-review notes:

Pregnancy or breastfeeding
Pregnancy or breastfeeding warrants medical review or avoidance for DSIP. [1][2][3][4]
Untreated sleep apnea
Untreated sleep apnea warrants medical review or avoidance for DSIP. [1][2][3][4]
Use with sedatives without clinician review
Use with sedatives without clinician review warrants medical review or avoidance for DSIP. [1][2][3][4]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

Sleep meds / sedatives / alcohol
Benzodiazepines, Z-drugs, antihistamine sleep aids, alcohol, or sedating supplements can compound next-day impairment; this is a theoretical neuroactive caution. [1][2][3][4]
Opioids / gabapentinoids
Opioids, gabapentin, or pregabalin can raise the consequence of added sleepiness or poor coordination; this is a theoretical neuroactive caution. [1][2][3][4]
Stimulants / caffeine
Stimulants or high caffeine can counter sleep effects and make sleep-response tracking unreliable; this is a theoretical neuroactive caution. [1][2][3][4]

Regulatory status

United States

In the U.S. as of 2026-06-21, DSIP is not FDA-approved for the reviewed injectable route. FDA compounding safety-risk materials flag this substance or close naming variant, so the 503A row should be read as a safety-risk bucket, not approval. [19][13][14][17][18]

Route	FDA drug approval	503A compounding
Injectable	Not Approved DSIP is not FDA-approved as an injectable drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval. [13][14][17][18]	Flagged FDA safety-risk materials flag emideltide/DSIP for immunogenicity, peptide impurities, API-characterization complexity, and insufficient proposed-route safety information. This is a 503A compounding safety-risk bucket, not FDA drug approval. [19][13][14][17][18]

Injectable

FDA drug approval

Not Approved

DSIP is not FDA-approved as an injectable drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval. [13][14][17][18]

503A compounding

Flagged

FDA safety-risk materials flag emideltide/DSIP for immunogenicity, peptide impurities, API-characterization complexity, and insufficient proposed-route safety information. This is a 503A compounding safety-risk bucket, not FDA drug approval. [19][13][14][17][18]

International

EU/Europe, UK, Canada, and Australia require product-specific checks in EMA/MHRA, Health Canada, and TGA registers. Research-market, supplement, or compounded availability should not be treated as therapeutic approval in those markets. [20][21][22][23]

Sports & competition

WADA S0 can apply to non-approved pharmacological substances that are not otherwise named. Tested athletes should not treat DSIP injectable route as athlete-cleared without sport-specific review. [15][13][14][17][18]

How it works

DSIP has been studied around sleep architecture, stress-axis modulation, pain, and neuroendocrine signaling. In practical terms, the proposed mechanism is state regulation across sleep and stress systems rather than the direct receptor action of a sedative-hypnotic drug. [1][2][3][4]

Injectable use keeps the exposure question separate from old sleep-lab observations. Because the receptor target remains diffuse and modern dose-ranging evidence is thin, the mechanism can explain research interest but cannot carry strong insomnia or recovery claims by itself. Modern trials would need to define both exposure and measurable sleep endpoints. [1][2][3][4]

Research gaps & open questions

What the current literature has not yet settled about DSIP:

A key evidence gap is modern randomized insomnia studies. [1][2][3][4]

A key evidence gap is clear receptor and pharmacokinetic characterization. [1][2][3][4]

A key evidence gap is interactions with sedatives, alcohol, and psychiatric medications. [1][2][3][4]

Common questions

Is DSIP FDA-approved for sleep?

No. DSIP is not FDA-approved in the U.S. for sleep, and FDA lists emideltide/DSIP with compounding safety concerns. [13][14][1][2][19][17]

Does DSIP force sleep?

No. DSIP is not a sedative-hypnotic drug; the sleep evidence is older, mixed, and not a modern insomnia protocol. [13][14][1][2]

Can DSIP be combined with sleep medications?

No established safety standard exists. Sedatives, alcohol, and other sleep medications need clinician review because combination safety is not well defined. [13][14][1][2]

Myths & misconceptions

Myth

The name proves it induces sleep.

Reality

The name reflects early research history, not a guaranteed clinical effect. [1][2][3][4]

Myth

A neuropeptide is safer than sleep medication.

Reality

Limited safety data and interactions still matter. [1][2][3][4]

History & discovery

DSIP was named from early work linking a peptide fraction with delta-wave sleep, then tested in small sleep and pain studies. Its history is old, intriguing, and still unresolved. [1][2][3][4]

Clinical studies tested DSIP in chronic insomnia, 24-hour sleep-wake behavior, and pronounced pain episodes. Those studies created human interest but did not mature into an approved insomnia drug. [1][2][3][4]

Later reviews repeatedly treated DSIP as a mechanistic puzzle rather than a settled therapy. That history explains why modern claims need caution around receptor target, dose, and endpoints. [1][2][3][4]

Published research 15 studies

[1]

Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study.

Neuropsychobiology, 1992. human clinical.

[2]

Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia.

Eur Neurol, 1987. human clinical.

[3]

Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study.

Eur Neurol, 1984. human clinical.

[4]

Delta sleep-inducing peptide.

Eur J Anaesthesiol, 2001 Jul. review.

[5]

Delta sleep-inducing peptide (DSIP): a still unresolved riddle.

J Neurochem, 2006 Apr. review.

[6]

Delta-sleep-inducing peptide (DSIP): an update.

Peptides, 1986 Nov-Dec. review.

[7]

Delta-sleep-inducing peptide (DSIP): a review.

Neurosci Biobehav Rev, 1984 Spring. review.

[8]

DSIP--a tool for investigating the sleep onset mechanism: a review.

Int J Neurosci, 1988 Feb. review.

[9]

The effects of delta-sleep-inducing peptide (DSIP) on wakefulness and sleep patterns in the cat.

Brain Res, 1987 Jun 30. review.

[10]

Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke.

Molecules, 2021 Aug 26. animal.

[11]

Comparison of DSIP- (delta sleep-inducing peptide) and P-DSIP-like (phosphorylated) immunoreactivity in cerebrospinal fluid of patients with senile dementia of Alzheimer type, multi-infarct syndrome, communicating hydrocephalus and Parkinson's disease.

J Neurol, 1987 Oct. human clinical.

[12]

Production and immunohistochemical application of monoclonal antibodies against delta sleep-inducing peptide.

J Chem Neuroanat, 1992 Nov-Dec. review.

[13]

Drugs@FDA/openFDA query for DSIP

U.S. Food and Drug Administration. database query.

[14]

Compounding and the FDA: Questions and Answers

U.S. Food and Drug Administration. official guidance.

[15]

The 2026 List of Prohibited Substances and Methods

World Anti-Doping Agency. regulatory.